Shawn K. Singh, J.D., Chief Executive Officer, Director
Mr. Singh has over 20 years of experience working with private and public biotechnology and pharmaceutical companies, a life sciences venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. Prior to joining us as Chief Executive Officer in August 2009, Mr. Singh served as Managing Principal of Cato BioVentures, the venture capital affiliate of Cato Research, a profitable, global, full-service CRO for which he served as Chief Business Officer and General Counsel. Mr. Singh also served as Chief Business Officer of SciClone Pharmaceuticals (NASDAQ: SCLN), a US-based, China-focused specialty pharmaceutical company with a substantial revenue-generating and profitable commercial business and a marketed product portfolio of differentiated therapies for oncology, infectious diseases and cardiovascular disorders, and as President and director of Echo Therapeutics (NASDAQ: ECTE), a medical device company developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for use in hospital critical care units and for people with diabetes. Mr. Singh began his career as a corporate finance attorney in the Silicon Valley offices of Morrison & Foerster LLP, an international law firm. He is a member of the State Bar of California.
H. Ralph Snodgrass, Ph.D., Co-Founder, President and Chief Scientific Officer, Director
Dr. Snodgrass co-founded VistaGen with Dr. Gordon Keller in 1998 and served as our Chief Executive Officer until August 2009. He has 20 years of experience in senior biotechnology management, including as Chief Scientific Officer of Progenitor, Inc. He has more than 10 years of research experience as a professor at the Lineberger Comprehensive Cancer Center, University North Carolina Chapel Hill School of Medicine, and as a member of the Institute for Immunology, Basel, Switzerland. Dr. Snodgrass is a past Board Member of the Emerging Company Section of the Biotechnology Industry Organization (BIO), and is a published and recognized pioneering expert in stem cell biology with more than 20 years’ experience in the uses of stem cells as biological tools for drug discovery and development.
Jerrold D. Dotson, CPA, Chief Financial Officer, Secretary
Mr. Dotson brings a broad base of financial experience to VistaGen, joining as our Chief Financial Officer in September 2011. Most recently, he served as Corporate Controller for Discovery Foods. Mr. Dotson also held various positions in the finance and administration department of Calypte Biomedical Corporation, including his last position as Vice President of Finance and Administration and Corporate Secretary, California & Hawaiian Sugar Company, and The Clorox Company. He received his B.S. degree (Cum Laude) in accounting from Abilene Christian College and is a certified public accountant licensed in the State of California.